0
0
DEHRADUN: An Indian pharmaceutical company has refuted claims that it supplied armodafinil to Singapore, following reports of hospitalizations linked to the drug in the city-state. The company, based in India, asserts that it has never exported the medication outside of the country.
This denial comes in the wake of investigations by Singaporean health authorities into a cluster of hospitalizations suspected to be connected to the consumption of armodafinil. The drug, commonly used to treat excessive daytime sleepiness associated with conditions like narcolepsy, has raised concerns after several individuals in Singapore experienced adverse effects.
The Indian pharmaceutical firm, whose name has not been disclosed in the initial reports, has stated unequivocally that its distribution of armodafinil is strictly limited to the domestic market. Company representatives emphasized that they adhere to all regulatory guidelines and have comprehensive tracking systems in place to monitor the distribution of their products.
“We have rigorous internal controls to ensure our products are only distributed within India,” a company spokesperson reportedly stated. “We are fully cooperating with any inquiries and are prepared to provide all necessary documentation to demonstrate our compliance.”
Singaporean authorities are now working to trace the source of the armodafinil found in the affected individuals. Investigations are focusing on determining whether the drug was imported through unauthorized channels or if it was sourced from other suppliers.
The incident has prompted heightened scrutiny of pharmaceutical supply chains and the potential risks associated with unregulated drug distribution. It has also highlighted the importance of robust pharmacovigilance systems to monitor and respond to adverse drug reactions.
The Indian company’s denial adds a layer of complexity to the ongoing investigation, raising questions about the true origin of the armodafinil linked to the Singapore hospitalizations. As the investigation progresses, further details are expected to emerge.
Disclaimer: This news article is based on information available from the provided source. Further investigations and official statements may alter the facts presented. The information provided is for general knowledge and informational purposes only, and does not constitute medical advice. Readers should consult with qualified healthcare professionals for any health concerns or before making any decisions related to their health or treatment.
(https://timesofindia.indiatimes.com/city/dehradun/singapore-armodafinil-hospitalisation-indian-pharma-company-claims-never-supplied-drug-outside-country/articleshow/118989902.cms)
